Watchlist for June 2, 2008

See one of the recent 'Chart Reading' posts for some potential swing candidates. Also be sure to check my typical swing trade entry & exit rules.

Potential day trades:

(From Briefing.com)

Gapping Down

In reaction to disappointing earnings/guidance: AGYS -13.8%... Select European financial names showing weakness: RBS -6.7% and BCS -4.5% (Royal Bank Of Scotland, Barclays raided by UK OFT, according to TV - DJ), UBS -2.2%, ING -1.9%... Select European drug stocks trading lower: SHPGY -5.5%, GSK -1.8%, AZN -1.7%... Other news: HRS -12.2% (issues statement that it isn't pursuing a merger or sale of co), SOL -9.6% (files for a 9 mln share ADS secondary offering; 8.14 mln ADS are being offered by the co and 860K ADS are being offered by selling shareholders; also downgraded to Underweight at Morgan Stanley), IMCL -7.4% (ERBITUX data demonstrate improved overall survival in first-line treatment of advanced non-small cell lung cancer), MAR -5.0% (sees North American RevPAR growth of approximately 2%, compared to prior company guidance of 3-5%), ASML -2.6% (still checking), MT -1.5% (still checking), VOD -1.5% (Telkom SA in Talks With Vodafone, Mvelaphanda - Bloomberg.com), NOK -1.4% (still checking)... Analyst downgrades: UIS -5.1% (downgraded to Underperform at Merrill), BPFH -3.6% (downgraded to Underperform at Merrill), LDK -3.1% (downgraded to Equal Weight at Morgan Stanley), IFX -3.1% (downgraded to Hold at Citigroup), PMCS -2.5% (downgraded to Sell at Merrill), LEH -1.9% (downgraded to Underperform at Merrill), IDTI -1.6% (downgraded to Sell at Merrill), LSI -1.4% (downgraded to Sell at Merrill), MPG -1.3% (downgraded to Underperform at Merrill).

Gapping Up

In reaction to strong earnings/guidance: CNXT +19.6%, LGF +1.0%... Select biotech/pharma names showing strength with multiple ASCO presentations out: ACOR +20.6% (announces positive data from second Ph. 3 study for Fampridine-SR on walking ability in people with MS), IDMI +10.0% (announces Phase 2 follow-up data showing IDM-2101 is well tolerated with positive survival trend and announces data supporting improved overall survival advantage for Metastatic Osteosarcoma treated with Mifamurtide), AVAN +4.9%, PARD +3.0% (announces safety and efficacy results from a previously unpublished Phase 1 clinical trial of picoplatin and liposomal doxorubicin in patients with advanced solid tumors, including ovarian cancer), NVS +2.8% (reports findings from a Ph. 2 study show that RAD001 enhances tumor shrinkage when given in combination with letrozole tablets), NKTR +2.5% (new "positive" data announced for NKTR-102 highlights promise of its small molecule PEG-oncolytics), DNA +2.3% (Second Ph. 3 study of Avastin plus chemotherapy shows improved progression-free survival in women with advanced HER2-negative breast cancer)... Other news: CPST +6.6% (announces first order for new C1000; value order value exceeded $2 mln), EXTR +4.6% (announces "victory" in patent litigation), GM +4.4% (mentioned positively in Barron's), ABMD +4.2% (Receives 510k clearance from FDA for Impella 2.5 Device), CSIQ +4.1% (signs $500 million supply agreement with Neo Solar Power), HOV +3.9% (Cramer makes positive comments on MadMoney), MSPD +3.7% (announces 1-for-5 reverse stock split), SNE +3.2% (showed strength in overseas trading following tier 1 upgrade on Friday)... Analyst upgrades: MEE +2.9% (upgraded to Outperform at FBR), SOV +2.8% (upgraded to Outperform at Keefe Bruyette), ARCC +2.5% (upgraded to Buy at Merrill), YGE +1.7% (upgraded to Buy at Citigroup), SNTA +1.6% (initiated with a Positive at Susquehanna Financial), ORCC +1.5% (upgraded to Buy at Merrill), TSO +1.3% (upgraded to Hold at Deutsche Bank), ANR +1.3% (upgraded to Overweight at Morgan Stanley), MS +0.9% (upgraded to Buy at Merrill).

Disclaimer & How I use this list